The post Plasma Struggles to Reclaim Post-TGE Momentum appeared on BitcoinEthereumNews.com. After a highly successful launch, the XPL token has fallen almost 50% from its opening week high. Stablecoin-focused Layer 1 blockchain Plasma debuted its XPL token two weeks ago, and following an impressive post-TGE surge to a $17 billion fully diluted valuation (FDV), the token has since been bleeding. XPL launched on Sept. 25 and doubled from its opening price of roughly $0.8 to a high of $1.67 in the following days, rewarding ICO participants with a 3300% return on their investments. However, since that peak, the token has struggled and currently trades at $0.87, or an $8.7 billion valuation, a 47% drop from its all-time high. The token has greatly underperformed the broader market, with BTC rising almost 12% between Sept. 27 and Oct. 4 while XPL plunged 49%. XPL Chart – CoinGecko It is unclear whether there is a specific catalyst for the token’s muted performance after such an explosive start, and Plasma’s representatives referred The Defiant back to founder Paul Faecks’ X post, where he denied allegations that the Plasma team sold tokens or that controversial market-making firm Wintermute was involved. While Faecks has ruled out any potential foul play, some contributing factors to the selloff could include liquidity incentive emissions, which payout more than $1 million per day in XPL, or ICO whales selling large quantities of tokens, as the sale structure controversially allowed individuals to purchase up to 10% of the initial $500 million cap. As a result, the first Plasma ICO vault filled instantly, and the team increased the deposit cap from $500 million to $1 billion while still allowing individual investors to purchase massive quantities of the token, which were completely unlocked on Sept. 25. Key Metrics Remain Strong Despite the token’s struggles over the last week, the network itself continues to grow,… The post Plasma Struggles to Reclaim Post-TGE Momentum appeared on BitcoinEthereumNews.com. After a highly successful launch, the XPL token has fallen almost 50% from its opening week high. Stablecoin-focused Layer 1 blockchain Plasma debuted its XPL token two weeks ago, and following an impressive post-TGE surge to a $17 billion fully diluted valuation (FDV), the token has since been bleeding. XPL launched on Sept. 25 and doubled from its opening price of roughly $0.8 to a high of $1.67 in the following days, rewarding ICO participants with a 3300% return on their investments. However, since that peak, the token has struggled and currently trades at $0.87, or an $8.7 billion valuation, a 47% drop from its all-time high. The token has greatly underperformed the broader market, with BTC rising almost 12% between Sept. 27 and Oct. 4 while XPL plunged 49%. XPL Chart – CoinGecko It is unclear whether there is a specific catalyst for the token’s muted performance after such an explosive start, and Plasma’s representatives referred The Defiant back to founder Paul Faecks’ X post, where he denied allegations that the Plasma team sold tokens or that controversial market-making firm Wintermute was involved. While Faecks has ruled out any potential foul play, some contributing factors to the selloff could include liquidity incentive emissions, which payout more than $1 million per day in XPL, or ICO whales selling large quantities of tokens, as the sale structure controversially allowed individuals to purchase up to 10% of the initial $500 million cap. As a result, the first Plasma ICO vault filled instantly, and the team increased the deposit cap from $500 million to $1 billion while still allowing individual investors to purchase massive quantities of the token, which were completely unlocked on Sept. 25. Key Metrics Remain Strong Despite the token’s struggles over the last week, the network itself continues to grow,…

Plasma Struggles to Reclaim Post-TGE Momentum

After a highly successful launch, the XPL token has fallen almost 50% from its opening week high.

Stablecoin-focused Layer 1 blockchain Plasma debuted its XPL token two weeks ago, and following an impressive post-TGE surge to a $17 billion fully diluted valuation (FDV), the token has since been bleeding.

XPL launched on Sept. 25 and doubled from its opening price of roughly $0.8 to a high of $1.67 in the following days, rewarding ICO participants with a 3300% return on their investments.

However, since that peak, the token has struggled and currently trades at $0.87, or an $8.7 billion valuation, a 47% drop from its all-time high. The token has greatly underperformed the broader market, with BTC rising almost 12% between Sept. 27 and Oct. 4 while XPL plunged 49%.

XPL Chart – CoinGecko

It is unclear whether there is a specific catalyst for the token’s muted performance after such an explosive start, and Plasma’s representatives referred The Defiant back to founder Paul Faecks’ X post, where he denied allegations that the Plasma team sold tokens or that controversial market-making firm Wintermute was involved.

While Faecks has ruled out any potential foul play, some contributing factors to the selloff could include liquidity incentive emissions, which payout more than $1 million per day in XPL, or ICO whales selling large quantities of tokens, as the sale structure controversially allowed individuals to purchase up to 10% of the initial $500 million cap.

As a result, the first Plasma ICO vault filled instantly, and the team increased the deposit cap from $500 million to $1 billion while still allowing individual investors to purchase massive quantities of the token, which were completely unlocked on Sept. 25.

Key Metrics Remain Strong

Despite the token’s struggles over the last week, the network itself continues to grow, and is now the sixth largest ecosystem in DeFi with $6.4 billion in total value locked (TVL), particularly led by its Aave vaults, which command $4.5 billion, or 70% of the chain’s DeFi TVL.

The lending vault currently offers users more than 8% APY, but the yield was as high as 50% at TGE and 20% the day after, with rewards distributed from Plasma, Aave, and Veda.

Source: https://thedefiant.io/news/blockchains/plasma-struggles-to-reclaim-post-tge-momentum

Market Opportunity
Plasma Logo
Plasma Price(XPL)
$0.08128
$0.08128$0.08128
+0.22%
USD
Plasma (XPL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26